UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...

UCB and Biogen’s drug dapirolizumab pegol has met the primary endpoint of improvement in disease activity in lupus patients.

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global ...

异常散点图：患儿入院当天进行血常规检查，检验人员在审核血常规报告时发现血常规三系均减低，同时注意到白细胞散点图异常，表现为在中性粒区域左下方和淋巴区域正下方有异常细胞团（红色圈内），疑似异常细胞和有核红细胞… ...

CD40 配体 (CD40L) 抗体市场调研报告呈现了全球与中国CD40 配体 (CD40L) 抗体市场规模发展趋势。2023年全球CD40 配体 (CD40L) 抗体市场规模达到71.65亿元（人民币），中国CD40 配体 (CD40L) 抗体市场规模达x.x亿元，同时报告中也给出了2023年中国CD40 配体 (CD40L) 抗体进口和 ...

Similarly, the universities portfolio in Preclinical comprises 2 molecule. CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily.

The key targets in the Pancreatic Islet Transplant Rejection pipeline products market include Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre ...